Anixa Biosciences Inc (ANIX) 10-K Annual Report Fri Jan 11 2019

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Oct. 31, 2018	Jan. 09, 2019	Apr. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Anixa Biosciences Inc
Document Type	10-K
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		19,292,264
Entity Public Float			$ 56,459,801
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Oct. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/715446/000151316219000016/form10k.htm

View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Financial

Legal

Revenue

M & A

Other

Filter by Subcategory:

All

Earnings

Expense

Cash Flow

Product

Dividend

Other

Inside Anixa Biosciences Inc's 10-K Annual Report:

Financial - Earnings Highlight
Accordingly, the earnings process from these licenses was complete and 100% of the revenue was recognized upon execution of the license agreement.

Financial - Earnings Highlight
As such, the earnings process was determined to be complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met.
Other - Other Highlight
The net loss attributable to noncontrolling interest of approximately $247,000 in fiscal year 2018 represents Wistars 5% ownership interest in Certaintys net loss for the fiscal year.
Legal - Other Highlight
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion activities increased by approximately $663,000 in fiscal year 2018, to approximately $768,000, from approximately $105,000 in fiscal year 2017.
Financial - Expense Highlight
During the years ended October 31, 2018 and 2017 we recorded consulting expense related to stock options granted to consultants of approximately $261,000 and $3,000, respectively, and consulting expense related to stock awards granted to consultants of approximately $15,000 and $32,000, respectively.
Financial - Cash Flow
We can give no assurance...Read more
Revenue - Product
The increase was primarily due...Read more
Financial - Cash Flow
The impairment in carrying amount...Read more
Financial - Expense
As of October 31, 2018,...Read more
Financial - Expense
General and administrative expenses increased...Read more
Financial - Expense
During the years ended October...Read more
Financial - Dividend
The difference between the fair...Read more
Financial - Expense
As of October 31, 2018,...Read more
Other - Other
Wistar?s interest in Certainty commenced...Read more
Financial - Dividend
The deemed dividend to preferred...Read more
Revenue - Product
Additionally, the sale of equity...Read more
Financial - Expense
The increase in research and...Read more
Revenue - Product
Cash provided by financing activities...Read more
Other - Other
As a result, our cash,...Read more
Financial - Expense
Research and development expenses are...Read more
M & A - Other
If current cash on hand,...Read more
M & A - Other
The gain on extinguishment of...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 21: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001513162-19-000016
Submitted to the SEC: Fri Jan 11 2019 11:31:23 AM EST
Accepted by the SEC: Fri Jan 11 2019
Period: Wednesday, October 31, 2018
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-19-000016.htm

Anixa Biosciences Inc (ANIX) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, October 31, 2018

SEC Filings

ANIX Valuations

ANIX Annual Reports

ANIX Quarterly Reports

ANIX Corporate News